Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02799095 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
A Phase 1 study, sponsored by Mural Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 243
- Enrollment target
NCT02799095 is a Phase 1 study that has completed, run by Mural Oncology. The registered enrollment target is 243 participants.
The verdict
NCT02799095, a Phase 1 study, has completed, sponsored by Mural Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 243 participants
- Enrollment target
Study Summary
To better understand the safety and tolerability of ALKS 4230 in humans
Interventions
- DRUG ALKS 4230
- DRUG ALKS 4230 + pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2016-09-14 |
| Est. Completion | 2023-08-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02799095
The ClinicalTrials.gov registry entry for NCT02799095 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mural Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ALKS 4230 is the first listed.
NCT02799095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02799095 about?
NCT02799095 is a clinical study titled "A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors". To better understand the safety and tolerability of ALKS 4230 in humans
What is the current status of trial NCT02799095?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 243 participants. The study started on 2016-09-14. Estimated completion is 2023-08-02.
What interventions are being tested in trial NCT02799095?
The interventions under investigation include: ALKS 4230 (DRUG), ALKS 4230 + pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02799095?
This trial is sponsored by Mural Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.